Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Glucagon-like peptide 1--a cardiologic dimension

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Symptoms and healthcare contact preceding sudden cardiac death in persons aged 1-49 years

    Research output: Contribution to journalReviewResearchpeer-review

  2. Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD?

    Research output: Contribution to journalEditorialResearchpeer-review

  3. An overview of current and emerging devices for percutaneous left atrial appendage closure

    Research output: Contribution to journalReviewResearchpeer-review

  4. β-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.
Original languageEnglish
JournalTrends in Cardiovascular Medicine
Volume20
Issue number1
Pages (from-to)8-12
Number of pages5
ISSN1050-1738
DOIs
Publication statusPublished - 1 Jan 2010

ID: 32169059